Hamedifard, Z. and Farrokhian, A. and Reiner, A. and Bahmani, F. and Asemi, Z. and Ghotbi, M. and Taghizadeh, M. (2020) The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. Lipids in Health and Disease, 19 (1).
|
Text
document(2).pdf Download (692kB) | Preview |
Abstract
Background: The present research aimed to analyze the impacts of magnesium and zinc supplements on glycemic control, serum lipids, and biomarkers of oxidative stress and inflammation in patients suffering from coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM). Methods: According to the research design, a randomized, double-blind, placebo-controlled trial has been implemented on 60 subjects suffering from CHD and T2DM. Therefore, participants have been randomly divided into 2 groups for taking placebo (n = 30) or 250 mg magnesium oxide plus 150 mg zinc sulfate (n = 30) for 12 weeks. Results: Magnesium and zinc significantly decreased fasting plasma glucose (FPG) (β - 9.44 mg/dL, 95 CI, - 18.30, - 0.57; P = 0.03) and insulin levels (β - 1.37 μIU/mL, 95 CI, - 2.57, - 0.18; P = 0.02). Moreover, HDL-cholesterol levels significantly enhanced (β 2.09 mg/dL, 95 CI, 0.05, 4.13; P = 0.04) in comparison to the placebo. There was an association between magnesium and zinc intake, and a significant decrease of C-reactive protein (CRP) (β - 0.85 mg/L, 95 CI, - 1.26, - 0.45; P < 0.001), a significant increase in total nitrite (β 5.13 μmol/L, 95 CI, 1.85, 8.41; P = 0.003) and total antioxidant capacity (TAC) (β 43.44 mmol/L, 95 CI, 3.39, 83.50; P = 0.03) when compared with placebo. Furthermore, magnesium and zinc significantly reduced the Beck Depression Inventory index (BDI) (β - 1.66; 95 CI, - 3.32, - 0.009; P = 0.04) and Beck Anxiety Inventory (BAI) (β - 1.30; 95 CI, - 2.43, - 0.16; P = 0.02) when compared with the placebo. Conclusions: In patients with T2DM and CHD, the 12-week intake of magnesium plus zinc had beneficial effects on FPG, HDL-cholesterol, CRP, insulin, total nitrite, TAC levels, and BDI and BAI score. This suggests that magnesium and zinc co-supplementation may be beneficial for patients with T2DM and CHD. Further studies on more patients and lasting longer are needed to determine the safety of magnesium and zinc co-supplementation. Trial registration: Current Controlled Trials http://www.irct.ir: IRCT20130211012438N31 at 11 May 2019 of registration. This study retrospectively registered. © 2020 The Author(s).
| Item Type: | Article |
|---|---|
| Additional Information: | cited By 0 |
| Uncontrolled Keywords: | antioxidant; C reactive protein; glucose; glutathione; high density lipoprotein cholesterol; insulin; low density lipoprotein cholesterol; magnesium oxide; malonaldehyde; nitrite; placebo; triacylglycerol; very low density lipoprotein cholesterol; zinc sulfate, adult; aged; Article; Beck Anxiety Inventory; Beck Depression Inventory; controlled study; double blind procedure; female; glucose blood level; glycemic control; high density lipoprotein cholesterol level; homeostasis model assessment; human; inflammation; insulin blood level; ischemic heart disease; lipid blood level; low density lipoprotein cholesterol level; major clinical study; metabolic parameters; mineral supplementation; non insulin dependent diabetes mellitus; oxidative stress; Quantitative Insulin Sensitivity Check Index; randomized controlled trial; triacylglycerol blood level |
| Subjects: | Nutrition Biochemistry, Genetics and Molecular Biology Pharmacology, Toxicology and Pharmaceutics |
| Divisions: | Faculty of Medicine > Basic Sciences > Department of Biochemistry |
| Depositing User: | ART . editor |
| Date Deposited: | 27 Jun 2020 12:48 |
| Last Modified: | 27 Jun 2020 12:48 |
| URI: | http://eprints.kaums.ac.ir/id/eprint/4913 |
Actions (login required)
 |
View Item |
